

09-15-05

#

IFW

PATENTS

C.C.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Agoston et al.

Serial No. 09/644,387

Filed: August 23, 2000

For: Methods of Obtaining 2-Methoxyestradiol  
of High Purity

)  
)  
)  
)  
)

Art Unit: 1513

Examiner: Badio, Barbara P.

**INFORMATION DISCLOSURE STATEMENT**

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

As this Information Disclosure Statement is being filed after the issuance of an office action on the merits, pursuant to 37 C.F.R. §1.97(c)(2), the fee of \$180, as set forth in §1.17(p), is due. Form PTO-2038 authorizing the charge of \$180 is enclosed herewith.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Kilpatrick Stockton LLP  
1100 Peachtree Street, Ste. 2800  
Atlanta, Georgia 30309-4530  
(404) 815-6500  
Our Docket: 05213-0541 (43170-219662)

Respectfully submitted,

*Shirley E. Brosmore*  
Shirley E. Brosmore  
Reg. No. 56,167

09/19/2005 EAVALEW1 00000009 09644387  
01 FC:1806  
180.00 0P

---

Express Mail Mailing Label: EV 334681178 US  
Date of Deposit: September 14, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)</p> <p style="text-align: center;"><i>SEP 14 2005</i></p> <p style="text-align: right;">U.S. PATENT &amp; TRADEMARK OFFICE</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	1	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)			
	1	3,166,577		Ringold et al.	01/19/1965	
	2	3,562,260		De Ruggieri et al.	02/09/1971	
	3	4,444,767		Torelli et al.	04/24/1984	
	4	4,552,758		Murphy et al.	11/12/1985	
	5	4,634,705		DeBernardis et al.	01/06/1987	
	6	4,808,402		Leibovich et al.	02/28/1989	
	7	5,629,327		D'Amato	05/13/1997	
	8	5,629,340		Kuwano et al.	05/13/1997	
	9	5,639,725		O'Reilly et al.	06/17/1997	
	10	5,646,136	A	Petrow	07/08/1997	
	11	5,716,981		Hunter et al.	02/10/1998	
	12	5,733,876		O'Reilly et al.	03/31/1998	
	13	5,763,432		Tanabe et al.	06/09/1998	
	14	5,776,704		O'Reilly et al.	07/07/1998	
	15	5,792,845		O'Reilly et al.	08/11/1998	
	16	5,837,682		O'Reilly	11/17/1998	
	17	5,854,205		O'Reilly et al.	12/29/1998	
	18	5,854,221		Cao et al.	12/29/1998	
	19	5,861,372		Folkman et al.	01/19/1999	
	20	5,885,795		O'Reilly et al.	03/23/1999	
	21	5,919,459	A	Nacy et al.	07/06/1999	
	22	5,958,892		Mukhopadhyay et al.	09/28/1999	
	23	6,011,023		Clark et al.	01/04/2000	
	24	6,046,186		Tanabe et al.	04/04/2000	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known		
				Application No.		09/644,387
				Filing Date		08/23/2000
				First Named Inventor		Agoston et al.
				Group Art Unit		1617
				Examiner Name		Badio, Barbara
Sheet	2	of	24	Attorney Docket Number		05213-0541 (43170-219662)

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	25	6,051,726	A	Sachdeva et al.	04/18/2000	
	26	6,054,598		Sachdeva et al.	04/25/2000	
	27	6,239,123		Green et al.	05/29/2001	
	28	6,284,789	B1	LaLonde et al.	09/04/2001	
	29	6,346,510	B1	O'Reilly et al.	02/12/2002	
	30	6,399,773	B1	Liu et al.	06/04/2002	
	31	6,410,029	B1	Mukhopadhyay et al.	06/25/2002	
	32	6,413,513	B1	Holiday, John	07/02/2002	
	33	6,514,971	B1	Thomas et al.	02/04/2003	
	34	6,528,676	B1	D'Amato et al.	03/04/2003	
	35	6,605,622	B2	Green et al.	08/12/2003	
	36	6,723,858	B2	D'Amato et al.	04/20/2004	
	37	6,730,665	B1	Maran et al.	05/04/2004	
	38	6,908,910	B2	D'Amato et al.	06/21/2005	
	39	2002/0002294	A1	D'Amato et al.	01/03/2002	
	40	2002/0165212	A1	D'Amato et al.	11/07/2002	
	41	2003/0027803	A1	Slaga et al.	02/06/2003	
	42	2003/0096800	A1	D'Amato et al.	05/22/2003	
	43	2003/0236408	A1	D'Amato et al.	12/25/2003	
	44	2004/0072813	A1	D'Amato et al.	04/15/2004	
	45	2004/0214807	A1	D'Amato et al.	10/28/2004	
	46	2005/0020555	A1	D'Amato et al.	01/27/2005	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>						Complete if Known	
						Application No.	09/644,387
						Filing Date	08/23/2000
						First Named Inventor	Agoston et al.
						Group Art Unit	1617
						Examiner Name	Badio, Barbara
Sheet	3	of	24	Attorney Docket Number			05213-0541 (43170-219662)

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	47	DE	2 004 516		VEB Jenapharm	09/10/1970		No
	48	DE	27 57 157		Schering AG	12/19/1977		
	49	EP	0657175	A2	Centro de Immunologia Molecular	06/14/1995		
	50	EPO	0166937	A2	Abbott Laboratories	08/01/1986		
	51	GB	857,080		Syntex S.A.	12/29/1960		
	52	GB	857,081		Syntex S.A.	12/29/1960		
	53	GB	1,570,597		Takeda et al.	07/02/1980		
	54	JP	42-928	B	DAINIPPON PHARM CO LTD (abstract only)	01/18/1967		
	55	JP	39-5480	B	Teikoku Hormone Mfg. Co.			No
	56	JP	09316000	A	Toagosei Co. Ltd.	09/12/1997		
	57	JP	58-131978		Lilly & Co Eli (Eli)	08/06/1983		No
	58	JP	63090763	A	Research Development Corp. of Japan (Abstract only)	04/21/1988		
	59	JP	63-119500		Dai Ichi Seiyaku Co Ltd.	05/24/1988		No

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)</p>					Complete if Known	
					Application No.	09/644,387
					Filing Date	08/23/2000
					First Named Inventor	Agoston et al.
					Group Art Unit	1617
					Examiner Name	Badio, Barbara
Sheet	4	of	24		Attorney Docket Number	05213-0541 (43170-219662)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Kind Code <sup>4</sup> (if known)				
	60	JP	41 000100	A	Dainippon Pharmaceutical Co., Ltd. (abstract only)	01/07/1966	
	61	JP -	11-209322			08/03/1999	No
	62	SU	1240038	A1	A MED ONCOLOGY CENTRE (abstract only)	10/27/1996	
	63	WO	00/07576	A2	ENDORECHERCHE, INC	02/17/2000	
	64	WO	00/10552	A2	Global Vascular Concepts, Inc.	03/02/2000	
	65	WO	00/66095	A2	Sterix Limited	11/09/2000	
	66	WO	00/68246	A1	Research Institute for Medicine and Chemistry Inc.	11/16/2000	
	67	WO	87/02367	A3	The Upjohn Company	04/23/1987	
	68	WO	88/08002	A1	The Upjohn Company	10/20/1988	
	69	WO	93/19746	A1	ORION-YH-TYMA OY	10/14/1993	
	70	WO	98/32763	A1	SRI International	07/30/1998	
	71	WO	99/01142	A1	Hyal Pharmaceutical Corporation	01/14/1999	
	72	WO	99/22728	A1	Arch Development Corporation	05/14/1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>					Complete if Known	
					Application No.	09/644,387
					Filing Date	08/23/2000
					First Named Inventor	Agoston et al.
					Group Art Unit	1617
					Examiner Name	Badio, Barbara
Sheet	5	of	24		Attorney Docket Number	05213-0541 (43170-219662)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Kind Code <sup>4</sup> (if known)				
	73	WO	99/33858	A3	SRI International	07/08/1999	
	74	WO	99/33859	A2	SRI International	07/08/1999	
	75	WO	99/35150	A3	Arizona Board of Regents	07/15/1999	
	76	WO	99/45018	A1	Imclone Systems Incorporated	09/10/1999	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	6	of	24	Attorney Docket Number	05213-0541 (43170-219662)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	77	<b>Author:</b> <u>Publ:</u> <u>Research Plus Catalog</u>	<b>Title:</b>  <b>Vol/Iss:</b> <b>Pages:</b> 50-58 <b>Date:</b> 1993		
	78	<b>Author:</b> <u>Publ:</u> <u>Genetic Engineering News</u>	<b>Title:</b> News Article: Hoffman-La Roche Signs \$70 Million Deal with Millenium on Genomics Technology  <b>Vol/Iss:</b> <b>Pages:</b> <b>Date:</b> 4/15/1994		
	79	<b>Author:</b> <u>Publ:</u> <u>Genetic Engineering News</u>	<b>Title:</b> News Article: Advanced Drug Delivery Systems Peak Interest of Pharmaceutical & Biotech Firms  <b>Vol/Iss:</b> <b>Pages:</b> <b>Date:</b> 4/15/1994		
	80	<b>Author:</b> <u>Publ:</u> <u>Genetic Engineering News</u>	<b>Title:</b> News Article: Nasal Spray for Treating Bleeding Disorders  <b>Vol/Iss:</b> <b>Pages:</b> <b>Date:</b> 4/15/1994		
	81	<b>Author:</b> ABOULWAFA et al. <u>Publ:</u> <u>Steroids</u>	<b>Title:</b> Synthesis and evaluation for uterotrophic and antiimplantation activities of 2-substituted estradiol derivatives  <b>Vol/Iss:</b> 57 <b>Pages:</b> 199-204 <b>Date:</b> 04/1992		
	82	<b>Author:</b> ALGIRE, G.H. et al. <u>Publ:</u> <u>Journal of the National Cancer Institute</u>	<b>Title:</b> Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants  <b>Vol/Iss:</b> 6 <b>Pages:</b> 73-85 <b>Date:</b> 08/1945		
	83	<b>Author:</b> ALIEV et al. <u>Publ:</u> <u>Chemical Abstracts</u>	<b>Title:</b> 54929q Synthesis of cycloalkyl derivatives of dihydric phenols and their ethers  <b>Vol/Iss:</b> 72 <b>Pages:</b> 370 <b>Date:</b> 1970		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	7	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	84	<b>Author:</b> ANSTEAD et al. <b>Publ:</b> <u>Steroids</u>	<b>Title:</b> The Estradiol Pharmacophore: Ligand Structure-Estrogen Receptor Binding Affinity Relationships and a Model for the Receptor Binding Site		
	85	<b>Author:</b> ARNOLDI et al. <b>Publ:</b> <u>Journal of Agric. Food Chem.</u>	<b>Title:</b> Sweet Isovanillyl Derivatives: Synthesis and Structure-Taste Relationships of Conformationally Restricted Analogs (Abstract only)		
	86	<b>Author:</b> ATTALLA et al. <b>Publ:</b> <u>Biochemical and Biophysical Research Communications</u>	<b>Title:</b> 2-Methoxyestradiol-Induced Phosphorylation of Bcl-2: Uncoupling from JNK/SAPK Activation (Abstract only)		
	87	<b>Author:</b> AUDIER et al. <b>Publ:</b> <u>Bulletin De La Societe Chimique De France</u>	<b>Title:</b> Orientation de la fragmentation en spectrometrie de masse par introduction de groupements fonctionnels. VII. - Ethenylencetals de ceto-2 steroïdes		
	88	<b>Author:</b> BARNES et al. <b>Publ:</b> <u>Infection and Immunity</u>	<b>Title:</b> Tumor Necrosis Factor Production in Patients with Leprosy		
	89	<b>Author:</b> BINDRA et al. <b>Publ:</b> <u>Journal of Medicinal Chemistry</u>	<b>Title:</b> Studies in Antifertility Agents. 8. Seco Steroids. 2, 5,6-Secoestradiol and Some Related Compounds		
	90	<b>Author:</b> BLICKENSTAFF et al. <b>Publ:</b> <u>Steroids</u>	<b>Title:</b> Synthesis of Some Analogs of Estradiol		
			<b>Vol/Iss:</b> 62	<b>Pages:</b> 268-303	<b>Date:</b> 1997
			<b>Vol/Iss:</b> 46(10)	<b>Pages:</b> 4002-4010	<b>Date:</b> 1998
			<b>Vol/Iss:</b> 247 (3)	<b>Pages:</b> 616-619	<b>Date:</b> 6/29/1998
			<b>Vol/Iss:</b> 10	<b>Pages:</b> 3088-3090	<b>Date:</b> 1965
			<b>Vol/Iss:</b> 60 (4)	<b>Pages:</b> 1441-1446	<b>Date:</b> 04/1992
			<b>Vol/Iss:</b> 18 (9)	<b>Pages:</b> 921-925	<b>Date:</b> 1975
			<b>Vol/Iss:</b> 46 (4,5)	<b>Pages:</b> 889-902	<b>Date:</b> 10/1985

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	8	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	91	<b>Author:</b> BOYCE et al. <b>Publ:</b> <u>Unknown</u>	<b>Title:</b> Some Preliminary Synthetical Studies with 5,6,7,8-Tetra-hydro-8-methylindane -1,5-dione		
	92	<b>Author:</b> BRANDI et al. <b>Publ:</b> <u>Calcif. Tissue Int.</u>	<b>Title:</b> Bone endothelial cells as estrogen targets (Abstract only)		
	93	<b>Author:</b> BREM, H. et al. <b>Publ:</b> <u>Journal of Neurosurgery</u>	<b>Title:</b> Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas		
	94	<b>Author:</b> BURROWS, N.P. <b>Publ:</b> <u>British Medical Journal</u>	<b>Title:</b> Thalidomide Modifies Disease		
	95	<b>Author:</b> CAMBIE et al. <b>Publ:</b> <u>Journal of the Chemical Society</u>	<b>Title:</b> Aromatic Steroids. Part II. Chromium Trioxide Oxidation of Some Oestra-1,3,5(10)-trienes		
	96	<b>Author:</b> CAMBIE et al. <b>Publ:</b> <u>J. Chem. Soc.</u>	<b>Title:</b> Aromatic Steroids. Part I. Oxidation Products of 3-Methoxyestra-1,3,5(10)-triene- 17 $\beta$ -yl Acetate		
	97	<b>Author:</b> COREY et al. <b>Publ:</b> <u>Tetrahedron Letters</u>	<b>Title:</b> Applications of N,N-Dimethylhydrazones to Synthesis. Use in Efficient, Positionally and Stereochemically Selective C-C Bond Formation; Oxidative Hydrolysis to Carbonyl Compounds		
			<b>Vol/Iss:</b>  <b>Pages:</b> 1	<b>Pages:</b> 4547-4553  <b>Date:</b> 1960	
			<b>Vol/Iss:</b>  <b>Pages:</b> 53 (5)	<b>Pages:</b> 312-317  <b>Date:</b> 1993	
			<b>Vol/Iss:</b>  <b>Pages:</b> 74	<b>Pages:</b> 441-446  <b>Date:</b> 03/01/91	
			<b>Vol/Iss:</b>  <b>Pages:</b> 307 (6909)	<b>Pages:</b> 939-940  <b>Date:</b> 10/09/93	
			<b>Vol/Iss:</b>  <b>Pages:</b> 9	<b>Pages:</b> 1234-1240  <b>Date:</b> 1969	
			<b>Vol/Iss:</b>  <b>Pages:</b> 2603-2608	<b>Pages:</b> 2603-2608  <b>Date:</b> 1968	
			<b>Vol/Iss:</b>  <b>Pages:</b> 1	<b>Pages:</b> 3-6  <b>Date:</b> 1976	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	9	of	24	Attorney Docket Number	05213-0541 (43170-219662)

#### **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>o</sup>
	98	<b>Author:</b> COREY et al.  <b>Publ:</b> <u>Tetrahedron Letters</u>	<b>Title:</b> Facile Conversion of N,N-Dimethylhydrazones to Carbonyl Compounds by Cupric Ion-Catalyzed Hydrolysis	<b>Vol/Iss:</b> 41	<b>Pages:</b> 3678-3668	<b>Date:</b> 1976
	99	<b>Author:</b> CRABBE, P.  <b>Publ:</b> <u>Chem. Ind.</u>	<b>Title:</b> Cotton effect of the styrene chromophore (Abstract only)	<b>Vol/Iss:</b> 27	<b>Pages:</b> 917-918	<b>Date:</b> 1969
	100	<b>Author:</b> D'AMATO, R.J. et al.  <b>Publ:</b> <u>Proceedings of the National Academy of Science</u> USA	<b>Title:</b> Thalidomide is an Inhibitor of Angiogenesis	<b>Vol/Iss:</b> 91	<b>Pages:</b> 4082-4085	<b>Date:</b> 04/01/94
	101	<b>Author:</b> DING et al.  <b>Publ:</b> <u>Endocrinology</u>	<b>Title:</b> Sex Hormone-Binding Globulin Mediates Prostate Androgen Receptor Action via a Novel Signaling Pathway (Abstract only)	<b>Vol/Iss:</b> 139 (1)	<b>Pages:</b> 213-218	<b>Date:</b> 1998
	102	<b>Author:</b> DURANI et al.  <b>Publ:</b> <u>Journal of Steroid Biochemistry</u>	<b>Title:</b> Seco-Oestradiols and Some Non-Steroidal Oestrogens: Structural Correlates of Oestrogenic Action	<b>Vol/Iss:</b> 11	<b>Pages:</b> 67-77	<b>Date:</b> 1979
	103	<b>Author:</b> EDER et al.  <b>Publ:</b> <u>Chem. Ber.</u>	<b>Title:</b> Synthese von Ostradiol (in German - No translation available)	<b>Vol/Iss:</b> 109	<b>Pages:</b> 2948-2953	<b>Date:</b> 1976
	104	<b>Author:</b> EL-TOMBARY .  <b>Publ:</b> <u>Arch. Pharm. Pharm. Med. Chem.</u>	<b>Title:</b> Synthesis, Uterotropic, And Antiuterotropic Activities &Some Estradiol Derivatives Containing Thiadiazole, Thiazoline, ad Thiazolidinone Moieties	<b>Vol/Iss:</b> 330 (9-10)	<b>Pages:</b> 295-302	<b>Date:</b> 1997

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	10	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T	
	105	<b>Author:</b> EMONS et al.  <b>Publ:</b> <u>FOCUS MHL</u>	<b>Title:</b> Modulation der hypophysaren Sekretion von Luteinisierendem Hormon (LH) durch Ostrogene	<b>Vol/Iss:</b> 3	<b>Pages:</b> 221-228	<b>Date:</b> 1986
	106	<b>Author:</b> ENJYOJI, K. et al.  <b>Publ:</b> <u>Biochemistry</u>	<b>Title:</b> Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly <sup>212</sup> -Phe <sup>243</sup> , of the third Kunitz Domain is a Heparin-Binding Site	<b>Vol/Iss:</b> 34 (17)	<b>Pages:</b> 5725-5735	<b>Date:</b> 1995
	107	<b>Author:</b> FANCHENKO et al.  <b>Publ:</b> <u>Byull. Eksp. Biol. Med.</u>	<b>Title:</b> Characteristics of the guinea pig uterus estrogen receptor system (Abstract only)	<b>Vol/Iss:</b> 85 (4)	<b>Pages:</b> 467-470	<b>Date:</b> 1978
	108	<b>Author:</b> FETIZON et al.  <b>Publ:</b> <u>Bull. Soc. Chim. FR.</u>	<b>Title:</b> Synthesis of 2-keto steroids (Abstract only)	<b>Vol/Iss:</b> 8	<b>Pages:</b> 3301-3306	<b>Date:</b> 1968
	109	<b>Author:</b> FEVIG et al.  <b>Publ:</b> <u>Journal of Organic Chemistry</u>	<b>Title:</b> A Short, Stereoselective Route to 16 $\alpha$ -(Substituted-alkyl)estradiol Derivatives	<b>Vol/Iss:</b> 52	<b>Pages:</b> 247-251	<b>Date:</b> 1987
	110	<b>Author:</b> FIELD et al.  <b>Publ:</b> <u>Nature</u>	<b>Title:</b> Effect of Thalidomide on the Graft versus Host Reaction	<b>Vol/Iss:</b> 211 (5055)	<b>Pages:</b> 1308-1310	<b>Date:</b> 09/17/66
	111	<b>Author:</b> FIESER et al.  <b>Publ:</b> <u>Organic Synthesis Collective Volume 3</u>	<b>Title:</b> N-Methylformanilide	<b>Vol/Iss:</b> 3	<b>Pages:</b> 590-591	<b>Date:</b> 1955

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	11	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
	112	<b>Author:</b> FLOHE et al. <b>Publ:</b> <u>Arzneimitte/Forschung (Germany West)</u> <b>Vol/Iss:</b> 31 (2) <b>Pages:</b> 315-320 <b>Date:</b> 01/01/81			
	113	<b>Author:</b> FOLKMAN et al. <b>Publ:</b> <u>Science</u> <b>Vol/Iss:</b> 221 <b>Pages:</b> 719-725 <b>Date:</b> 08/19/83			
	114	<b>Author:</b> FOLKMAN, J. <b>Publ:</b> <u>New England Journal of Medicine</u> <b>Vol/Iss:</b> 285 (21) <b>Pages:</b> 1182-1186 <b>Date:</b> 11/18/71			
	115	<b>Author:</b> FOLKMAN, J. et al. <b>Publ:</b> <u>Nature</u> <b>Vol/Iss:</b> 339 <b>Pages:</b> 58-61 <b>Date:</b> 05/04/89			
	116	<b>Author:</b> FOLKMAN, J. et al. <b>Publ:</b> <u>Annals of Surgery</u> <b>Vol/Iss:</b> 164(3) <b>Pages:</b> 491-502 <b>Date:</b> 09/01/66			
	117	<b>Author:</b> GADOSY et al. <b>Publ:</b> <u>Journal of Physical Chemistry</u> <b>Vol/Iss:</b> 103 <b>Pages:</b> 8834-8839 <b>Date:</b> 1999			
	118	<b>Author:</b> GANDHI et al. <b>Publ:</b> <u>Journal of Indian Chem. Soc.</u> <b>Vol/Iss:</b> 39 <b>Pages:</b> 306-308 <b>Date:</b> 1962			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	12	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	119	<b>Author:</b> GASLINI et al. <b>Publ:</b> <u>Journal of Organic Chemistry</u>	<b>Title:</b> Reaction of Eugenol with Synthesis Gas. Synthesis of 5,6,7,8-Tetrahydro -3-methoxy-2-naphthol	<b>Vol/Iss:</b> 29 (5) <b>Pages:</b> 1177-1180 <b>Date:</b> 05/1964	
	120	<b>Author:</b> GIAN TONDURY et al. <b>Publ:</b> <u>Cambridge Philosophical Society</u>	<b>Title:</b> Zur Wirkung Der Sexualhormone Auf Wachstum und Differenzierung (See English Summary Page 55)	<b>Vol/Iss:</b> <b>Pages:</b> 28-58 <b>Date:</b> 12/17/1955	
	121	<b>Author:</b> GIMBRONE, M.A. et al. <b>Publ:</b> <u>Journal of the National Cancer Institute</u>	<b>Title:</b> Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea	<b>Vol/Iss:</b> 52(2) <b>Pages:</b> 413-427 <b>Date:</b> 02/74	
	122	<b>Author:</b> GIMBRONE, M.A. et al. <b>Publ:</b> <u>Journal of Experimental Medicine</u>	<b>Title:</b> Tumor dormancy <i>in vivo</i> by Prevention of Neovascularization	<b>Vol/Iss:</b> 136 <b>Pages:</b> 261-276 <b>Date:</b> 1972	
	123	<b>Author:</b> GONZALEZ et al. <b>Publ:</b> <u>Steroids</u>	<b>Title:</b> Synthesis and Pharmacological Evaluation of 8 $\alpha$ Estradiol Derivatives	<b>Vol/Iss:</b> 40 (2) <b>Pages:</b> 171-187 <b>Date:</b> 9/1982	
	124	<b>Author:</b> GROSS, J.L. et al. <b>Publ:</b> <u>Proceedings of the American Association of  Cancer Research</u>	<b>Title:</b> Modulation of Solid Tumor Growth <i>in vivo</i> by bFGF (Abstract only)	<b>Vol/Iss:</b> 31 <b>Pages:</b> 79 <b>Date:</b> 03/90	
	125	<b>Author:</b> GUJJAR et al. <b>Publ:</b> <u>Annals of Clinical and Laboratory Science</u>	<b>Title:</b> The Effect of Estradiol on Candida albicans Growth	<b>Vol/Iss:</b> 27 (2) <b>Pages:</b> 151-156 <b>Date:</b> 1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
Sheet	13	of	24	Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
				Attorney Docket Number	05213-0541 (43170-219662)

<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	126	<b>Author:</b> GUNZLER, V. <b>Publ:</b> <u>Medical Hypothesis</u>	<b>Title:</b> Thalidomide-A Therapy for the Immunological Consequences of HIV Infection?		
			<b>Vol/Iss:</b> 30 (2)	<b>Pages:</b> 105-109	<b>Date:</b> 10/89
	127	<b>Author:</b> GUPTA et al. <b>Publ:</b> <u>Indian Journal of Chemistry</u>	<b>Title:</b> Antifertility Agents. XIV. Secosteroids. VII. Synthesis of 2 $\alpha$ and 2 $\beta$ , 6 $\beta$ -dimethyl- 3 $\beta$ -(p-hydroxyphenyl)-trans-bicyclo[4.3.0]nonan-7-ones and some related compounds (Abstract only)	<b>Pages:</b> 759-760	<b>Date:</b> 1975
	128	<b>Author:</b> GUPTA et al. <b>Publ:</b> <u>Indian Journal of Chemistry</u>	<b>Title:</b> Studies in Antifertility Agents. Part XVIII. 2 $\alpha$ 6 $\beta$ -Diethyl-3 $\beta$ -(p-hydroxyphenyl)-trans-bicyclo[4.3.0]nonan-7 $\beta$ -ol and 6 $\beta$ -methyl-3 $\beta$ -(p-hydroxyphenyl)-2 $\alpha$ -propyl- trans-bicyclo[4.3.0]nonan-7 $\beta$ -ol (Abstract only)	<b>Pages:</b> 886-890	<b>Date:</b> 1980
	129	<b>Author:</b> GUTIERREZ-RODRIGUEZ et al. <b>Publ:</b> <u>The Journal of Rheumatology</u>	<b>Title:</b> Treatment of Refractory Rheumatoid Arthritis - The Thalidomide Experience	<b>Pages:</b> 158-163	<b>Date:</b> 02/89
	130	<b>Author:</b> GUTIERREZ-RODRIGUEZ, O. <b>Publ:</b> <u>Arthritis and Rheumatism</u>	<b>Title:</b> Thalidomide - A Promising New Treatment for Rheumatoid Arthritis	<b>Pages:</b> 1118-1121	<b>Date:</b> 10/84
	131	<b>Author:</b> HAHNEL et al. <b>Publ:</b> <u>Journal of Steroid Biochemistry</u>	<b>Title:</b> The Specificity of the Estrogen Receptor of Human Uterus	<b>Pages:</b> 21-31	<b>Date:</b> 1973
	132	<b>Author:</b> HANDLEY et al. <b>Publ:</b> <u>British Journal of Dermatology</u>	<b>Title:</b> Chronic bullous disease of childhood and ulcerative colitis	<b>Pages:</b> 67-68	<b>Date:</b> 07/01/92

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	14	of	24	Attorney Docket Number	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				<sup>2</sup> T	
	133	<b>Author:</b> HE et al. <b>Publ:</b> <u>Bioorganic &amp; Medicinal Chemistry Letters</u>	<b>Title:</b> Novel Cytokine Release Inhibitors. PartII Steroids				
	134	<b>Author:</b> HEJAZ et al. <b>Publ:</b> <u>Journal of Medicinal Chemistry</u>	<b>Title:</b> Synthesis and Biological Activity of the Superestrogen (E)-17-Oximino-3-O-sulfamoyl-1,3,5(10)-estratriene: X-ray Crystal Structure of (E)-17-Oximino-3-hydroxy-1,3,5(10)-estratriene				
	135	<b>Author:</b> HENEY et al. <b>Publ:</b> <u>British Journal of Haematology</u>	<b>Title:</b> Thalidomide treatment for chronic graft-versus-host disease				
	136	<b>Author:</b> HOLKER et al. <b>Publ:</b> <u>J. Chem. Soc. Perkin Trans.</u>	<b>Title:</b> The Reactions of Estrogens with Benzeneseleninic Anhydride and Hexamethyldisilazane				
	137	<b>Author:</b> HU, G. <b>Publ:</b> <u>Proceedings of the National Academy of Sciences, USA</u>	<b>Title:</b> Neomycin Inhibits Angiogenin-induced Angiogenesis (abstract Only)				
	138	<b>Author:</b> IKEGAWA et al. <b>Publ:</b> <u>Biomed. Chromatogr.</u>	<b>Title:</b> Immunoaffinity extraction for liquid chromatographic determination of equulin and its metabolites in plasma (Abstract only)				
	139	<b>Author:</b> IMAMURA et al. <b>Publ:</b> <u>USPATFULL 76:20259 US 3,950,437</u>	<b>Title:</b> Method for Manufacture of Dihydric Phenols (Abstract only)				
			<b>Vol/Iss:</b>	<b>Pages:</b>	<b>Date:</b>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	15	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	140	<b>Author:</b> INGBER, D. et al. <u>Publ:</u> <u>Nature</u>	<b>Title:</b> Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth		
			<b>Vol/Iss:</b> 348	<b>Pages:</b> 555-557	<b>Date:</b> 12/06/90
	141	<b>Author:</b> IRIARTE et al. <u>Publ:</u> <u>Tetrahedron</u>	<b>Title:</b> Steroids (XCIV). Synthesis of 2-methyl and 1,2-dimethyl estrogens (Abstract only)		
			<b>Vol/Iss:</b> 3	<b>Pages:</b> 28-36	<b>Date:</b> 1958
	142	<b>Author:</b> JAGGERS et al. <u>Publ:</u> <u>Journal of Endocrinology</u>	<b>Title:</b> Potent Inhibitory Effects of Steroids in an in vitro Model of Angiogenesis (Abstract only)		
			<b>Vol/Iss:</b> 150 (3)	<b>Pages:</b> 457-464	<b>Date:</b> 1996
	143	<b>Author:</b> JHINGRAN et al. <u>Publ:</u> <u>Steroids</u>	<b>Title:</b> Studies in Antifertility Agents - Part XLI: Secosteroids-x: Syntheses of Various Stereoisomers of (+)-2,6β-diethyl-7α-ethynyl-3-(p-hydroxyphenyl)-trans-bicyclo [4.3.0]nonan-7β-ol.		
			<b>Vol/Iss:</b> 42 (6)	<b>Pages:</b> 627-634	<b>Date:</b> 1983
	144	<b>Author:</b> KARWAT <u>Publ:</u> <u>Caplus DE 1103310</u>	<b>Title:</b> Separation and Recovery of Hydrogen Sulfide from Hydrocarbon Mixture		
			<b>Vol/Iss:</b>	<b>Pages:</b>	<b>Date:</b> 09/02/1959
	145	<b>Author:</b> KATAOKA et al. <u>Publ:</u> <u>Cancer Research</u>	<b>Title:</b> An Agent that Increases Tumor Suppressor Transgene Product Coupled with Systemic Transgene Delivery Inhibits Growth of Metastatic Lung Cancer in Vivo (Abstract only)		
			<b>Vol/Iss:</b> 58 (21)	<b>Pages:</b> 4761-4765	<b>Date:</b> 11/1998
	146	<b>Author:</b> KNIGHTON, D. et al. <u>Publ:</u> <u>British Journal of Cancer</u>	<b>Title:</b> Avascular and Vascular Phases of Tumour Growth in the Chick Embryo		
			<b>Vol/Iss:</b> 35	<b>Pages:</b> 347-356	<b>Date:</b> 1977

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	16	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	147	<b>Author:</b> KOLE et al. <b>Publ:</b> <u>Journal of Medicinal Chemistry</u> <b>Vol/Iss:</b> 18 (7) <b>Pages:</b> 765-766 <b>Date:</b> 1975			
	148	<b>Author:</b> KOVACS et al. <b>Title:</b> Steroids. XXIII. Synthesis of 2- and 4-hydroxy and 2,4-dihydroxy derivatives of estrone and estradiol (Abstract only) <b>Publ:</b> <u>Acta Phys.Chem.</u> <b>Vol/Iss:</b> 19 (3) <b>Pages:</b> 287-290 <b>Date:</b> 1973			
	149	<b>Author:</b> LAGUCHEV, S.S. <b>Publ:</b> <u>Path.-Biol.</u> <b>Vol/Iss:</b> 9 (5-6) <b>Pages:</b> 638-640 <b>Date:</b> 03/1961			
	150	<b>Author:</b> LEWIS, Richard J. <b>Title:</b> <b>Publ:</b> <u>Hawley's Condensed Chemical Dictionary</u> <b>Vol/Iss:</b> <b>Pages:</b> 577 <b>Date:</b> 01/1993			
	151	<b>Author:</b> LEWIS, Richard J. <b>Title:</b> <b>Publ:</b> <u>Hawley's Condensed Chemical Dictionary</u> <b>Vol/Iss:</b> <b>Pages:</b> 128-129 <b>Date:</b> 01/1993			
	152	<b>Author:</b> LI, J., et al. <b>Title:</b> (DN 103:65176) Catechol Formation of Fluoro- and Bromo-substituted Estradiols by Hamster Liver Microsomes. Evidence for Dehalogenation. (Abstract only) <b>Publ:</b> <u>CAPLUS; Molecular Pharmacology</u> <b>Vol/Iss:</b> 27 (5) <b>Pages:</b> 559-565 <b>Date:</b> 1985			
	153	<b>Author:</b> LIEN, W. et al. <b>Title:</b> The blood supply of experimental liver metastases. II. A Microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber <b>Publ:</b> <u>Surgery</u> <b>Vol/Iss:</b> 68 (2) <b>Pages:</b> 334-340 <b>Date:</b> 08/1970			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	17	of	24	Attorney Docket Number	05213-0541 (43170-219662)

#### **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>2</sup>
	154	<b>Author:</b> LIMANTSEV et al.  <b>Publ:</b> <u>Akush Jinekol.</u>	<b>Title:</b> Effect of some estrogen structural analogs on the development of the mouse embryo (Abstract only)	<b>Vol/Iss:</b> 6	<b>Pages:</b> 55-56	<b>Date:</b> 1982
	155	<b>Author:</b> LIU et al.  <b>Publ:</b> <u>Tetrahedron Letters</u>	<b>Title:</b> Total Synthesis of (+-) -Δ <sup>9(12)</sup> -Capnellene	<b>Vol/Iss:</b> 26 (40)	<b>Pages:</b> 4847-4850	<b>Date:</b> 1985
	156	<b>Author:</b> LOOZEN et al.  <b>Publ:</b> <u>Recl.: J.R. Neth.Chem. Soc.</u>	<b>Title:</b> An approach to the synthesis of 7.β-amino estrogens (Abstract only)	<b>Vol/Iss:</b> 102 (10)	<b>Pages:</b> 433-437	<b>Date:</b> 1983
	157	<b>Author:</b> LOVELY et al.  <b>Publ:</b> <u>Journal of Medicinal Chemistry</u>	<b>Title:</b> 2-(Hydroxyalkyl)estradiols: Synthesis and Biological Evaluation	<b>Vol/Iss:</b> 39	<b>Pages:</b> 1917-1923	<b>Date:</b> 1996
	158	<b>Author:</b> MARO et al.  <b>Publ:</b> <u>Journal of Embryology and Experimental Morphology</u>	<b>Title:</b> Mechanism of Polar Body Formation in the Mouse Oocyte: An Interaction Between the Chromosomes, the Cytoskeleton and the Plasma Membrane	<b>Vol/Iss:</b> 92	<b>Pages:</b> 11-32	<b>Date:</b> 1986
	159	<b>Author:</b> MEZA et al.  <b>Publ:</b> <u>Drug Therapy</u>	<b>Title:</b> Managing the Gastrointestinal Complications of AIDS	<b>Vol/Iss:</b> 23 (11)	<b>Pages:</b> 74-83	<b>Date:</b> 11/1993
	160	<b>Author:</b> MICHEL et al.  <b>Publ:</b> <u>Biochem. Pharmacol.</u>	<b>Title:</b> Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists (Abstract only)	<b>Vol/Iss:</b> 36 (19)	<b>Pages:</b> 3175-3180	<b>Date:</b> 1987

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	18	of	24	Attorney Docket Number	
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T
	161	<b>Author:</b> MOLLENDORFF, W. VON <b>Title:</b> Wachstumsstorungen durch Geschlechtshormone, nach Untersuchungen an Gewebekulturen  <b>Publ:</b>				
	162	<b>Author:</b> MORISAKI et al. <b>Title:</b> Steroids. L1. Aromatization reaction of the cross-conjugated dienone system by Zinc 9. (Abstract only)  <b>Publ:</b> <u>Chem. Pharm. Bull.</u>				
	163	<b>Author:</b> NAAFS et al. <b>Title:</b> Thalidomide Therapy An Open Trial  <b>Publ:</b> <u>International Journal of Dermatology</u>				
	164	<b>Author:</b> NAMBARA et al. <b>Title:</b> Microbial transformation products derived from steriods. I. Synthesis of 1,2- and 3-dimethoxy-4-methylestratrienes (Abstract only)  <b>Publ:</b> <u>Chem. Pharm. Bull.</u>				
	165	<b>Author:</b> NAMBARA et al. <b>Title:</b> Synthesis of 16 $\beta$ -Oxygenated Catechol Estrogen Methyl Ethers, New and Potential Metabolites  <b>Publ:</b> <u>Chemical &amp; Pharmaceutical Bulletin</u>				
	166	<b>Author:</b> NAMBARA, T., et al. <b>Title:</b> DN 82:43650; Analytical Chemical Studies on Steroids. LXXXIII. Synthesis of Epimeric 2-Hydroxy-16-Chlorestrostrong Monomethyl Ethers (Abstract only)  <b>Publ:</b> <u>HCAPLUS-Chemical and Pharmaceutical Bulletin</u>				
	167	<b>Author:</b> NEWKOME et al. <b>Title:</b> Synthesis of Simple Hydrazones of Carbonyl Compounds by an Exchange Reaction  <b>Publ:</b> <u>Journal of Organic Chemistry</u>				

Examiner Signature		Date Considered
--------------------	--	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	19	of	24	Attorney Docket Number	05213-0541 (43170-219662)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
	168	<b>Author:</b> NGUYEN, M. et al. <b>Publ:</b> Journal of the National Cancer Institute	<b>Title:</b> Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients <b>Vol/Iss:</b> 85 (3) <b>Pages:</b> 241-242 <b>Date:</b> 02/03/93		
	169	<b>Author:</b> NUMAZAWA et al. <b>Publ:</b> Steroids	<b>Title:</b> Novel and Regiospecific Synthesis of 2-Amino Estrogens via Zincke Nitration <b>Vol/Iss:</b> 41 (5) <b>Pages:</b> 675-682 <b>Date:</b> 1983		
	170	<b>Author:</b> OMAR et al. <b>Publ:</b> European Journal of Medicinal Chemistry	<b>Title:</b> Synthesis, binding affinities and uterotrophic activity of some 2-substituted estradiol and ring-A-fused pyrone derivatives <b>Vol/Iss:</b> 29 <b>Pages:</b> 25-32 <b>Date:</b> 1994		
	171	<b>Author:</b> PERT et al. <b>Publ:</b> Australian Journal of Chemistry	<b>Title:</b> Preparations of 2,4-disubstituted estradiols (Abstract only) <b>Vol/Iss:</b> 42 (3) <b>Pages:</b> 421-432 <b>Date:</b> 1989		
	172	<b>Author:</b> PETERS et al. <b>Publ:</b> Journal of Medicinal Chemistry	<b>Title:</b> 17-Desoxy Estrogen Analogues <b>Vol/Iss:</b> 32 (7) <b>Pages:</b> 1642-1652 <b>Date:</b> 1989		
	173	<b>Author:</b> PFEIFFER et al. <b>Publ:</b> Journal of Endocrinology	<b>Title:</b> Are catechol estrogens obligatory mediators of estrogen action in the central nervous system? I. Characterization of pharmacological probes with different receptor binding affinities and catechol estrogen formation rates (Abstract only) <b>Vol/Iss:</b> 110 (3) <b>Pages:</b> 489-497 <b>Date:</b> 1986		
	174	<b>Author:</b> PLUM et al. <b>Publ:</b> Proceedings of the American Association for Cancer Research Annual.	<b>Title:</b> Vaccination with Peptide to the Heparin Binding Domain of bFGF Conjugated to Liposomes Inhibits bFGF Induced Neovascularization (Abstract only) <b>Vol/Iss:</b> 39 <b>Pages:</b> 8 <b>Date:</b> 03/1998		

Examiner Signature		Date Considered
--------------------	--	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	20	of	24	Attorney Docket Number	05213-0541 (43170-219662)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
	175	<b>Author:</b> POWELL et al. <b>Publ:</b> <u>British Journal of Dermatology</u>	<b>Title:</b> Investigation and Treatment of Orogenital Ulceration; studies on a Possible Mode of Action of Thalidomide  <b>Vol/Iss:</b> 113 Supp. 28 <b>Pages:</b> 141-144 <b>Date:</b> 07/1985		
	176	<b>Author:</b> ROMANELLI et al. <b>Publ:</b> <u>Organic Synthesis</u>	<b>Title:</b> Ethyl-p-Dimethylaminophenylacetate  <b>Vol/Iss:</b> 5 <b>Pages:</b> 552 <b>Date:</b> 10/24/1973		
	177	<b>Author:</b> SAKAKIBARA, KYOICHI <b>Publ:</b> <u>Chemical Abstracts</u>	<b>Title:</b> 2-Hydroxy-1,3,5(10)-estratriene derivatives (Abstract only) (Identifier: XP-002186126)  <b>Vol/Iss:</b> 60(1) <b>Pages:</b> <b>Date:</b> 01/06/64		
	178	<b>Author:</b> SATO et al. <b>Publ:</b> <u>Horm. Carcinog. II. Proceedings Int. Symp., 2nd (1996), Meeting Date 1994</u>	<b>Title:</b> Natural estrogens induce modulation of microtubules in Chinese hamster V79 cells in culture (Abstract only)  <b>Vol/Iss:</b> <b>Pages:</b> 454-457 <b>Date:</b> 1996		
	179	<b>Author:</b> SEAVER, Sally <b>Publ:</b> <u>Genetic Engineering News</u>	<b>Title:</b> Monoclonal Antibodies in Industry: More Difficult than Originally Thought  <b>Vol/Iss:</b> 14 <b>Pages:</b> 10 and 21 <b>Date:</b> 08/1994		
	180	<b>Author:</b> SEEGERS et al. <b>Publ:</b> <u>Joint MCI-1st Symposium, Third 1st International Symposium, Biology and Therapy of Breast Cancer</u>	<b>Title:</b> Cyclic-AMP and Cyclic-GMP Production in MCF-7 Cells Exposed to Estradiol-17 Beta, Catecholestrogens and Methoxy-Estrogens in MCF-7 Cells (Meeting Abstract only)  <b>Vol/Iss:</b> <b>Pages:</b> <b>Date:</b> 09/25/89		
	181	<b>Author:</b> SEEGERS et al. <b>Publ:</b> <u>Journal of Steroid Biochemistry and Molecular Biology</u>	<b>Title:</b> The Mammalian Metabolite, 2-methoxyestradiol, Affects P53 Levels and Apoptosis Induction in Transformed Cells but Not in Normal Cells (Abstract only)  <b>Vol/Iss:</b> 62 (4) <b>Pages:</b> 253-267 <b>Date:</b> 07/1997		

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	21	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
	182	<b>Author:</b> SHAH et al. <b>Publ:</b> <u>Journal of Medicinal Chemistry</u>	<b>Title:</b> (+/-)-(N-alkylamino)benzazepine Analogs: Novel Dopamine D1 Receptor Antagonists (Abstract only)	<b>Vol/Iss:</b> 38 (21) <b>Pages:</b> 4284-4293	<b>Date:</b> 10/13/95
	183	<b>Author:</b> SHISHKINA et al. <b>Publ:</b> <u>Khim.-Farm. Zh.</u>	<b>Title:</b> Synthesis and properties of condensed heterocyclic derivatives of estra-4, 9-dien-17.beta.-ol-3-one (Abstract only)	<b>Vol/Iss:</b> 8 (1) <b>Pages:</b> 7-11	<b>Date:</b> 1974
	184	<b>Author:</b> SIDKY et al. <b>Publ:</b> <u>Cancer Research</u>	<b>Title:</b> Inhibition of Angiogenesis by Interferons: Effects on Tumor- and Lymphocyte-induced Vascular Responses	<b>Vol/Iss:</b> 47 <b>Pages:</b> 5155-5161	<b>Date:</b> 10/01/87
	185	<b>Author:</b> SIRACUSA et al. <b>Publ:</b> <u>Journal of Embryology and Experimental Morphology</u>	<b>Title:</b> The Effect of Microtubule- and Microfilament-disrupting Drugs on Preimplantation Mouse Embryos (abstract Only)	<b>Vol/Iss:</b> 60 <b>Pages:</b> 71-82	<b>Date:</b> 12/1980
	186	<b>Author:</b> SOKER et al. <b>Publ:</b> <u>Cell</u>	<b>Title:</b> Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor	<b>Vol/Iss:</b> 92 <b>Pages:</b> 735-745	<b>Date:</b> 03/20/1998
	187	<b>Author:</b> SPYRIOUNIS et al. <b>Publ:</b> <u>Arch. Pharm.</u>	<b>Title:</b> Copper (II) complex of an estradiol derivative with potent antiinflammatory properties (Abstract only)	<b>Vol/Iss:</b> 324 (9) <b>Pages:</b> 533-536	<b>Date:</b> 1991
	188	<b>Author:</b> SRIVASTAVA, A. et al. <b>Publ:</b> <u>American Journal of Pathology</u>	<b>Title:</b> The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness (0.76-4.0 mm Thick) Skin Melanoma	<b>Vol/Iss:</b> 133 (2) <b>Pages:</b> 419-424	<b>Date:</b> 11/1988

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	22	of	24	Attorney Docket Number	05213-0541 (43170-219662)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	189	<b>Author:</b> STAPLES et al. <b>Publ:</b> <u>Steroids</u>	<b>Title:</b> Structural Requirements for Steroid Inhibition of Sheep Lymphocyte Mitogenesis in vitro  <b>Vol/Iss:</b> 44 (5) <b>Pages:</b> 419-433 <b>Date:</b> 11/1984		
	190	<b>Author:</b> STARKOV et al. <b>Publ:</b> <u>Zhurnal Prikladnoi Khimii</u>	<b>Title:</b> Mono- and Dialkylation of Guaiacol by Olefins on KU-2 Cation Exchanger (Abstract only)  <b>Vol/Iss:</b> 41 (3) <b>Pages:</b> 688-690 <b>Date:</b> 1968		
	191	<b>Author:</b> TAYLOR, S. et al. <b>Publ:</b> <u>Nature</u>	<b>Title:</b> Protamine is an Inhibitor of Angiogenesis  <b>Vol/Iss:</b> 297 <b>Pages:</b> 307-312 <b>Date:</b> 05/27/82		
	192	<b>Author:</b> TREMBLAY et al. <b>Publ:</b> <u>Synthetic Communications</u>	<b>Title:</b> A Convenient Synthetic Method for Alpha-Alkylation of Steroidal 17-Ketone: Preparation of 16 $\beta$ -(THPO-Heptyl)-Estradiol  <b>Vol/Iss:</b> 25 (16) <b>Pages:</b> 2483-2495 <b>Date:</b> 1995		
	193	<b>Author:</b> TREMBLAY et al. <b>Publ:</b> <u>Bioorganic &amp; Medicinal Chemistry</u>	<b>Title:</b> Synthesis of 16-(Bromoalkyl)-Estradiols Having Inhibitory Effect on Human Placental Estradiol 17 $\beta$ -Hydroxysteroid Dehydrogenase (17 $\beta$ -HSD Type 1)  <b>Vol/Iss:</b> 3 (5) <b>Pages:</b> 505-523 <b>Date:</b> 1995		
	194	<b>Author:</b> VICENTE et al. <b>Publ:</b> <u>Archives of Internal Medicine</u>	<b>Title:</b> In Vitro Activity of Thalidomide Against Mycobacterium avium Complex  <b>Vol/Iss:</b> 153 (4) <b>Pages:</b> 534 <b>Date:</b> 02/22/93		
	195	<b>Author:</b> WANG et al. <b>Publ:</b> <u>Shengwu Huaxue Zazhi</u>	<b>Title:</b> Photoaffinity Labeling of Human Placental Estradiol 17 $\beta$ -dehydrogenase with 2-And 4-azidoestrone, 2- and 4-azidoestradiol (abstract Only)  <b>Vol/Iss:</b> 8 (6) <b>Pages:</b> 715-718 <b>Date:</b> 1992		

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	23	of	24	Attorney Docket Number	05213-0541 (43170-219662)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	196	<b>Author:</b> WEIDNER, N. et al. <b>Publ:</b> <u>Journal of the National Cancer Institute</u>	<b>Title:</b> Tumor angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma <b>Vol/Iss:</b> 84 <b>Pages:</b> 1875-1887 <b>Date:</b> 12/16/92		
	197	<b>Author:</b> WEIDNER, N. et al. <b>Publ:</b> <u>American Journal of Pathology</u>	<b>Title:</b> Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma <b>Vol/Iss:</b> 143 (2) <b>Pages:</b> 401-409 <b>Date:</b> 08/1993		
	198	<b>Author:</b> WEIDNER, N. et al. <b>Publ:</b> <u>New England Journal of Medicine</u>	<b>Title:</b> Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma <b>Vol/Iss:</b> 324 (1) <b>Pages:</b> 1-8 <b>Date:</b> 01/03/91		
	199	<b>Author:</b> WELSCH et al. <b>Publ:</b> <u>Experientia</u>	<b>Title:</b> Staphylostatic Activity of Some New Diphenols, Naphthols, and Chalcones (Abstract only) <b>Vol/Iss:</b> 11 <b>Pages:</b> 350-351 <b>Date:</b> 1955		
	200	<b>Author:</b> WHITE et al. <b>Publ:</b> <u>The New England Journal of Medicine</u>	<b>Title:</b> Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a <b>Vol/Iss:</b> 32 (18) <b>Pages:</b> 1197-1200 <b>Date:</b> 05/04/89		
	201	<b>Author:</b> WIESE et al. <b>Publ:</b> <u>Journal of Medicinal Chemistry</u>	<b>Title:</b> Induction of the Estrogen Specific Mitogenic Response of MCF-7 Cells by Selected Analogues of Estradiol-17 $\beta$ : A 3D QSAR Study <b>Vol/Iss:</b> 40 <b>Pages:</b> 3659-3669 <b>Date:</b> 1997		
	202	<b>Author:</b> WURTZ et al. <b>Publ:</b> <u>Journal of Medicinal Chemistry</u>	<b>Title:</b> Three-Dimensional Models of Estrogen Receptor Ligand Binding Domain Complexes Based on Related Crystal Structures and Mutational and Structure-Activity Relationship Data <b>Vol/Iss:</b> 41 <b>Pages:</b> 1803-1814 <b>Date:</b> 1998		

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for Form 1449/A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application No.	09/644,387
				Filing Date	08/23/2000
				First Named Inventor	Agoston et al.
				Group Art Unit	1617
				Examiner Name	Badio, Barbara
Sheet	24	of	24	Attorney Docket Number	05213-0541 (43170-219662)
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T <sup>2</sup>
	203	<b>Author:</b> YASUDA et al. <b>Publ:</b> <i>Anat. Embryol. (Berl.)</i>	<b>Title:</b> Accelerated differentiation in seminiferous tubules of fetal mice prenatally exposed to ethinyl estradiol (Abstract only) <b>Vol/Iss:</b> 174 (3) <b>Pages:</b> 289-299 <b>Date:</b> 1986		

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.